Industrials · Medical Distributors

McKesson Corporation

NYSEMCK ISINUS58155Q1031 SEC CIK0000927653 Listed on NYSE · USD

$1,082.78 +2.99 (+0.28%) After hours $1,079.79 (-0.28%) ≈ ₹1.02 L a share

Open chart

Price, last 12 months+26.74% in a year

Key numbers

Market value: $125.01B
P/E (TTM): 27.9
Forward P/E: 23.1
EPS (TTM): $38.86
Dividend yield: 0.35%
Beta: 0.28
Day range: $1,077.64 – $1,090.90
52-week range: $723.68 – $1,121.50
Volume: 48,639
10-day avg volume: $770.00K
Revenue (TTM): $418.79B
EBITDA (TTM): $7.57B
Gross margin: 3.7%
Net margin: 1.3%
Return on equity: -180.6%
Debt / equity: -232.9%
Price / sales: 0.30
Shares out: 115.46M

52W low52W high

Quarterly results

Results for each quarter

Last 12 quarters from 10-Q and 10-K filings with the US SEC. Q4 = full year minus the first three quarters. Hover a bar to see the number.

Revenue and net income

$80.90B$642.00M$589.00M

Dec 23

$76.36B$1.22B$791.00M

Mar 24

$79.28B$1.03B$915.00M

Jun 24

$93.65B$578.00M$241.00M

Sep 24

$95.29B$1.22B$879.00M

Dec 24

$90.82B$1.59B$1.26B

Mar 25

$97.83B$1.04B$784.00M

Jun 25

$103.15B$1.41B$1.11B

Sep 25

$106.16B$1.62B$1.19B

Dec 25

$96.30B$2.15B$1.68B

Mar 26

$105.38B$1.32B$614.00M

Jun 26

$110.96B$1.60B$1.22B

Sep 26

Revenue · QoQ (vs last quarter)

—-5.6%+3.8%+18%+1.8%-4.7%+7.7%+5.4%+2.9%-9.3%+9.4%+5.3%

Revenue · YoY (vs a year ago)

————+18%+19%+23%+10%+11%+6.0%+7.7%+7.6%

Net income · QoQ (vs last quarter)

—+34%+16%-74%+265%+43%-38%+42%+6.8%+42%-63%+98%

Net income · YoY (vs a year ago)

————+49%+59%-14%+361%+35%+33%-22%+9.7%

RevenueOperating incomeNet incomeLine = trend

US$	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
Revenue	$80.90B	$76.36B	$79.28B	$93.65B	$95.29B	$90.82B	$97.83B	$103.15B	$106.16B	$96.30B	$105.38B	$110.96B
Cost of revenue	$77.75B	$72.77B	$76.13B	$90.40B	$92.01B	$87.18B	$94.55B	$99.61B	$102.47B	$92.25B	$101.70B	$107.00B
Gross profit	$3.15B	$3.59B	$3.15B	$3.25B	$3.28B	$3.64B	$3.28B	$3.54B	$3.69B	$4.04B	$3.69B	$3.96B
Gross margin	3.9%	4.7%	4.0%	3.5%	3.4%	4.0%	3.4%	3.4%	3.5%	4.2%	3.5%	3.6%
Selling, general & admin	$2.51B	$2.19B	$2.00B	$2.50B	$2.03B	$1.98B	$2.20B	$2.07B	$2.03B	$1.80B	$2.26B	$2.27B
Operating income	$642.00M	$1.22B	$1.03B	$578.00M	$1.22B	$1.59B	$1.04B	$1.41B	$1.62B	$2.15B	$1.32B	$1.60B
Operating margin	0.8%	1.6%	1.3%	0.6%	1.3%	1.8%	1.1%	1.4%	1.5%	2.2%	1.3%	1.4%
Interest expense	$64.00M	$80.00M	$75.00M	$78.00M	$67.00M	$45.00M	$49.00M	$74.00M	$63.00M	$61.00M	$77.00M	$105.00M
Pre-tax income	$612.00M	$1.17B	$1.08B	$534.00M	$1.23B	$1.52B	$1.05B	$1.40B	$1.63B	$2.13B	$1.31B	$1.56B
Income tax	$-18.00M	$340.00M	$124.00M	$247.00M	$298.00M	$209.00M	$220.00M	$232.00M	$380.00M	$270.00M	$276.00M	$266.00M
Net income	$589.00M	$791.00M	$915.00M	$241.00M	$879.00M	$1.26B	$784.00M	$1.11B	$1.19B	$1.68B	$614.00M	$1.22B
Net margin	0.7%	1.0%	1.2%	0.3%	0.9%	1.4%	0.8%	1.1%	1.1%	1.7%	0.6%	1.1%
EPS (diluted)	$4.42	—	$7.00	$1.87	$6.95	—	$6.25	$8.92	$9.59	—	$5.15	$10.44

Income statement

Results for each year

8 fiscal years from the company's 10-K filings with the US SEC.

Revenue, gross profit and net income

$214.32B$11.75B$34.00M

FY19

$231.05B$12.02B$900.00M

FY20

$238.23B$12.15B$-4.54B

FY21

$263.97B$13.13B$1.11B

FY22

$276.71B$12.36B$3.56B

FY23

$308.95B$12.83B$3.00B

FY24

$359.05B$13.32B$3.30B

FY25

$403.43B$14.55B$4.76B

FY26

Revenue · YoY (vs a year ago)

—+7.8%+3.1%+11%+4.8%+12%+16%+12%

Net income · YoY (vs a year ago)

—+2,547%-604%+125%+220%-16%+9.8%+45%

RevenueGross profitNet incomeLine = trend

$0.17

FY19

$4.95

FY20

$-28.26

FY21

$7.23

FY22

$25.03

FY23

$22.39

FY24

$25.72

FY25

$38.38

FY26

EPS (diluted) · YoY (vs a year ago)

—+2,812%-671%+126%+246%-11%+15%+49%

EPS (diluted)Line = trend

US$	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	$214.32B	$231.05B	$238.23B	$263.97B	$276.71B	$308.95B	$359.05B	$403.43B
Revenue growth	—	7.8%	3.1%	10.8%	4.8%	11.7%	16.2%	12.4%
Cost of revenue	$202.57B	$219.03B	$226.08B	$250.84B	$264.35B	$296.12B	$345.73B	$388.88B
Gross profit	$11.75B	$12.02B	$12.15B	$13.13B	$12.36B	$12.83B	$13.32B	$14.55B
Gross margin	5.5%	5.2%	5.1%	5.0%	4.5%	4.2%	3.7%	3.6%
Research & development	$71.00M	$96.00M	—	—	—	—	—	—
Selling, general & admin	$8.44B	$9.18B	$8.85B	$10.54B	$7.78B	$8.66B	$8.51B	$8.10B
Operating income	$886.00M	$2.49B	$-5.04B	$2.04B	$4.38B	$3.91B	$4.42B	$6.21B
Operating margin	0.4%	1.1%	-2.1%	0.8%	1.6%	1.3%	1.2%	1.5%
Depreciation & amortisation	$317.00M	$335.00M	$344.00M	$312.00M	$272.00M	$279.00M	$272.00M	$287.00M
Interest expense	$264.00M	$249.00M	$217.00M	$178.00M	$248.00M	$252.00M	$265.00M	$247.00M
Pre-tax income	$610.00M	$1.14B	$-5.03B	$1.93B	$4.63B	$3.79B	$4.36B	$6.20B
Income tax	$356.00M	$18.00M	$-695.00M	$636.00M	$905.00M	$629.00M	$878.00M	$1.10B
Tax rate	58.4%	1.6%	—	33.0%	19.5%	16.6%	20.1%	17.8%
Net income	$34.00M	$900.00M	$-4.54B	$1.11B	$3.56B	$3.00B	$3.30B	$4.76B
Net margin	0.0%	0.4%	-1.9%	0.4%	1.3%	1.0%	0.9%	1.2%
EPS (diluted)	$0.17	$4.95	$-28.26	$7.23	$25.03	$22.39	$25.72	$38.38

Balance sheet

Assets and debt

At each fiscal year end.

Equity, debt and cash

$8.09B$7.60B$2.98B

FY19

$5.09B$7.39B$4.02B

FY20

$-21.00M$6.41B$6.28B

FY21

$-2.27B$5.88B$3.53B

FY22

$-1.86B$5.59B$4.68B

FY23

$-1.97B$5.63B$4.58B

FY24

$-2.07B$5.65B$5.69B

FY25

$-2.17B$6.53B$3.98B

FY26

Shareholders' equity · YoY (vs a year ago)

—-37%-100%-10,719%+18%-6.1%-5.2%-4.7%

Shareholders' equityTotal debtCash + short-term investmentsLine = trend

US$	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Cash & equivalents	$2.98B	$4.02B	$6.28B	$3.53B	$4.68B	$4.58B	$5.69B	$3.98B
Current assets	$38.47B	$42.22B	$45.38B	$46.23B	$44.29B	$47.97B	$55.40B	$57.21B
Total assets	$59.67B	$61.25B	$65.02B	$63.30B	$62.32B	$67.44B	$75.14B	$82.32B
Current liabilities	$37.63B	$42.62B	$44.10B	$48.47B	$47.96B	$52.36B	$61.60B	$67.02B
Long-term debt	$7.27B	$6.34B	$6.41B	$5.88B	$5.59B	$5.63B	$5.65B	$6.53B
Short-term debt	$330.00M	$1.05B	—	—	—	—	—	—
Total debt	$7.60B	$7.39B	$6.41B	$5.88B	$5.59B	$5.63B	$5.65B	$6.53B
Shareholders' equity	$8.09B	$5.09B	$-21.00M	$-2.27B	$-1.86B	$-1.97B	$-2.07B	$-2.17B
Current ratio	1.02	0.99	1.03	0.95	0.92	0.92	0.90	0.85
Debt / equity	0.94	1.45	—	—	—	—	—	—
Return on equity	0.4%	17.7%	—	—	—	—	—	—

Cash flow

Cash coming in and going out

Free cash flow = cash from operations minus capital spending. Shareholder returns = dividends + buybacks.

Free cash flow and shareholder returns

$4.04B$3.61B$1.93B

FY19

$4.37B$4.01B$2.23B

FY20

$4.54B$4.09B$1.02B

FY21

$4.43B$4.05B$3.79B

FY22

$5.16B$4.77B$3.93B

FY23

$4.31B$3.88B$3.34B

FY24

$6.09B$5.55B$3.49B

FY25

$6.16B$5.72B$5.13B

FY26

Operating cash flow · YoY (vs a year ago)

—+8.4%+3.8%-2.4%+16%-16%+41%+1.2%

Free cash flow · YoY (vs a year ago)

—+11%+2.0%-1.1%+18%-19%+43%+3.1%

Operating cash flowFree cash flowDividends + buybacksLine = trend

US$	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Cash from operations	$4.04B	$4.37B	$4.54B	$4.43B	$5.16B	$4.31B	$6.09B	$6.16B
Capital spending	$-426.00M	$-362.00M	$-451.00M	$-388.00M	$-390.00M	$-431.00M	$-537.00M	$-436.00M
Free cash flow	$3.61B	$4.01B	$4.09B	$4.05B	$4.77B	$3.88B	$5.55B	$5.72B
FCF margin	1.7%	1.7%	1.7%	1.5%	1.7%	1.3%	1.5%	1.4%
Cash from investing	$-1.38B	$-579.00M	$-415.00M	$-89.00M	$-542.00M	$-1.07B	$-733.00M	$-3.43B
Cash from financing	$-2.23B	$-2.73B	$-1.69B	$-6.32B	$-4.37B	$-3.34B	$-3.97B	$-4.63B
Dividends paid	$-292.00M	$-294.00M	$-276.00M	$-277.00M	$-292.00M	$-314.00M	$-345.00M	$-381.00M
Share buybacks	$-1.64B	$-1.93B	$-742.00M	$-3.52B	$-3.64B	$-3.03B	$-3.15B	$-4.75B

About

About McKesson Corporation

McKesson Corporation is an American publicly traded company that distributes pharmaceuticals and provides health information technology, medical supplies, and health management tools. The company delivers a third of all pharmaceutical products used or consumed in North America and employs over 80,000 employees. With $308.9 billion in 2024 revenue, it is the ninth-largest company by revenue in the United States and the nation's largest health care company. The company is headquartered in Irving, Texas. It is a component of the S&P 500 and is listed on the New York Stock Exchange, where it is traded under the ticker symbol "MCK".

From Wikipedia (CC BY-SA 4.0).

Company details

Company name: McKesson Corporation
Ticker: MCK
Exchange: NYSE
ISIN: US58155Q1031
SEC CIK: 0000927653
Sector: Industrials
Industry: Medical Distributors
SEC industry (SIC): Wholesale-drugs, Proprietaries & Druggists' Sundries (5122)
Incorporated in: Delaware
Financial year ends: 31 March
Filer type: Large accelerated filer
Latest annual report (10-K): 8 May 2026
CEO: Brian S. Tyler
Chair: Brian S. Tyler
Headquarters: Irving
Address: 6555 State Highway 161, Irving, Tx 75039
Founded: 1833
Employees: 43,000
Formerly known as: Mckesson Hboc Inc
Trades in: US dollars (USD)
Website: mckesson.com

News

Peers

Others in Industrials

Quotes from CNBC (may be delayed), financials from SEC EDGAR, profile from global-stock-logos (MIT). Information only, not investment advice.

India, Wall Street, crypto and commodities, live.

Every product, one clear workflow.

Built from data, on the record.

A clearer view of the markets.

Calculators and tools that show the maths.

Read the numbers, not the noise.

McKesson Corporation

Key numbers

Quarterly results

Revenue and net income

Income statement

Revenue, gross profit and net income

Balance sheet

Equity, debt and cash

Cash flow

Free cash flow and shareholder returns

About

Company details

News

Peers